Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5200495
Max Phase: Preclinical
Molecular Formula: C43H43F3N10O7
Molecular Weight: 868.87
Associated Items:
ID: ALA5200495
Max Phase: Preclinical
Molecular Formula: C43H43F3N10O7
Molecular Weight: 868.87
Associated Items:
Canonical SMILES: C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(=O)CCCCNc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)cc3OC)ncc2C(F)(F)F)c1
Standard InChI: InChI=1S/C43H43F3N10O7/c1-3-34(57)49-25-8-6-9-26(22-25)50-38-29(43(44,45)46)24-48-42(53-38)51-30-14-13-27(23-33(30)63-2)54-18-20-55(21-19-54)36(59)12-4-5-17-47-31-11-7-10-28-37(31)41(62)56(40(28)61)32-15-16-35(58)52-39(32)60/h3,6-11,13-14,22-24,32,47H,1,4-5,12,15-21H2,2H3,(H,49,57)(H,52,58,60)(H2,48,50,51,53)
Standard InChI Key: XXBWDTDSMDBAQK-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 868.87 | Molecular Weight (Monoisotopic): 868.3268 | AlogP: 5.45 | #Rotatable Bonds: 15 |
Polar Surface Area: 207.30 | Molecular Species: NEUTRAL | HBA: 13 | HBD: 5 |
#RO5 Violations: 3 | HBA (Lipinski): 17 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.59 | CX Basic pKa: 4.34 | CX LogP: 4.91 | CX LogD: 4.91 |
Aromatic Rings: 4 | Heavy Atoms: 63 | QED Weighted: 0.06 | Np Likeness Score: -1.08 |
1. Li Q, Guo Q, Wang S, Wan S, Li Z, Zhang J, Wu X.. (2022) Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686., 238 [PMID:35594654] [10.1016/j.ejmech.2022.114455] |
Source(1):